NCT06419491

Brief Summary

The context of HIV has changed dramatically this last two decades with the availability of highly active and well tolerated antiretroviral therapies, and the extension of prevention methods to include treatment as prevention of onward transmissions. It is time to test and treat as many HIV infected people as possible. HIV testing that target people known to have been exposed to HIV is an interesting option to explore to curb the spread of the epidemic. Notifying HIV exposed sexual partner for them to get an HIV test and treatment contribute to reduce HIV transmissions. The partner notification (PN) gives the opportunity to HIV positive partners to access to care and negative partners, access to prevention services. Several tools have been developed worldwide, in particular in the United Kingdom and the US, to help HIV or index patients to notify their sexual partner or needle-sharing people. This approach is new in France and PN intervention has to be assessed. The present study aimed to assess the effectiveness of a digital PN tool or a counselling interview to help men having sex with men (MSM) newly diagnosed for HIV to notify their exposed partners. The study also aimed to evaluate the acceptability of these PN intervention in index patients and their notified partners in the French context. To meet the objectives, an interventional study was developed in index patients (described above) coupled with :

  • an observational study in notified partners to assess their PN acceptability and their HIV testing uptake after being notified
  • a qualitative study in a sample of index patients and notified partner to assess more in depth their PN acceptability. Expected results and perspectives Feasible and effective, assisted PN services may complete HIV testing offer (and by extension sexually transmitted infections screening) as well as the prevention offer Pre-Exposure Prophylaxis (PrEP) for MSM. The study will provide information enabling the best practice guides. In a next step, PN interventions adapted to other key populations will be studied.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
400

participants targeted

Target at P50-P75 for not_applicable hiv-infections

Timeline
0mo left

Started Jun 2024

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress99%
Jun 2024May 2026

First Submitted

Initial submission to the registry

May 14, 2024

Completed
3 days until next milestone

First Posted

Study publicly available on registry

May 17, 2024

Completed
15 days until next milestone

Study Start

First participant enrolled

June 1, 2024

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 31, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 31, 2026

Last Updated

May 23, 2024

Status Verified

May 1, 2024

Enrollment Period

2 years

First QC Date

May 14, 2024

Last Update Submit

May 22, 2024

Conditions

Keywords

HIVPartner notification tools

Outcome Measures

Primary Outcomes (1)

  • The percentage of partners notified one month after the intervention, among the number of exposed partners stated by index patients

    An emailed invitation to complete an online self-administered questionnaire will be send to index patients to carry out an assessment of the notification process (number of partners exposed, contacted, notified, etc). Up to 3 reminders will be sent if no response.

    One month after the intervention

Secondary Outcomes (2)

  • Percentage of acceptability of partner notification by index patients

    One month after the intervention

  • Percentage of adverse events of partner notification reported by index patients

    One month after the intervention

Study Arms (2)

Digital notification tool

NO INTERVENTION

A partner notification digital tool allowing the sending of anonymous or personalised standardised text messages to partners and an information leaflet are provided to index patients

Digital notification tool and counseling

EXPERIMENTAL

In addition to the provision of the partner notification digital tool and the leaflet, a partner notification approach assisted by a trained counsellor during a specific counselling interview is offered to index patient.

Other: Partner notification by a trained counsellor

Interventions

One (or more if needed) interview with a partner notification trained counsellor is offered to index patients. During the interview, the counsellor gives information on partner notification, helps the index patients to remember their partners, to assess their HIV/sexually transmitted infection exposure and explains options to notify them. During the interview, the index patient can choose to entrust the notification of some of their partners to the counsellor. However, according to French law, provider referral is permitted only when it is anonymous. Therefore, this option is reserved to partners with a lot of partners in order to limit the risk of identifying the index patient

Digital notification tool and counseling

Eligibility Criteria

Age18 Years+
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • men
  • aged ≥18
  • having sex with ≥2 men in the last 12 months

You may not qualify if:

  • Persons who do not provide an email address, needed to receive the study questionnaires
  • Persons who do not speak or read French
  • Persons subject to a legal protection measure (guardianship, safeguard of justice)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

HIV Infections

Condition Hierarchy (Ancestors)

Blood-Borne InfectionsCommunicable DiseasesInfectionsSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System Diseases

Study Officials

  • Jade Ghosn, MD PhD

    AP-HP Hôpital Bichat Claude-Bernard, Paris, France

    STUDY DIRECTOR

Central Study Contacts

01 40 25 78 03 Ghosn, MD PhD

CONTACT

Karen Champenois, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 14, 2024

First Posted

May 17, 2024

Study Start

June 1, 2024

Primary Completion (Estimated)

May 31, 2026

Study Completion (Estimated)

May 31, 2026

Last Updated

May 23, 2024

Record last verified: 2024-05